In the A2780 in vitro model (Fig. 2) and primary ovarian cancer cells (Fig. 4), we hypothesized that their respective levels of DNA damage (and CP sensitivity) are predetermined by the differential import/export balance for the drug (pretarget resistance) rather than by modulating their DNA repair capacity (on‐target resistance). Here, CP is linked to ovarian cancer.